Not yet taking people in EgyptNo phase

Comparing Two Medicines, Apremilast and Adalimumab, in Psoriatic Arthritis

Compares apremilast and adalimumab, each given with methotrexate, in adults with psoriatic arthritis.

Key facts

Who runs it: Tanta University
Where: Tanta, EgyptSee the site
Trial code: NCT07398651
Registry title: Apremilast and Adalimumab in Psoriatic Arthritis Patients
Status: Not yet recruiting
People taking part: 60 people, planned
Starts: 30 Dec 2026
Expected to end: 30 Dec 2026
Type of study: Interventional, 2 groups
Treatments tested: Adalimumab
Apremilast
Record updated: 8 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with psoriatic arthritis whose joints, skin and nails are affected and who did not respond well enough to methotrexate. It compares Apremilast plus Methotrexate with Adalimumab plus Methotrexate.

Age: Over 18 years old, up to 70 years
Sex: All sexes can join.
Disease stage: Psoriatic arthritis that meets the CASPAR classification criteria. Joints, dactylitis, enthesitis, skin and nails are affected.
Earlier treatment: Methotrexate for at least 3 months with an inadequate response. No earlier biologic agents or Janus kinase inhibitors.

Main reasons for not taking part

Earlier treatment with biologic agents or Janus kinase inhibitors
Spine (axial) or eye involvement
Current or recent serious infection, including tuberculosis or hepatitis B/C
Cancer now or within the past five years
Pregnant or breastfeeding women, or women planning pregnancy during the study

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

This study will include 60 adult Psoriatic arthritis patients >18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months; Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains

Who cannot take part

Patients who received previous biologic agents or Janus kinase inhibitors
Current or recent serious infection including tuberculosis or hepatitis B/C
Current or past history of malignancy (within five year)
Severe uncontrolled comorbidities such as heart failure, severe liver disease, or chronic kidney disease (eGFR <30 mL/min/1.73m²)
Patients with axial and ocular involvement
Pregnant or breastfeeding women or women planning pregnancy during the study period

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 70 years old?

Where in Egypt

Tanta universityTanta, EgyptContact: MennaAllah Elmalla, Assistant lecturerNo longer taking part

About the trial

What the trial wants to find out

The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate

The 2 groups in the trial

Group ITreatment being tested
consists of 30 PsA patients who will receive Adalimumab with methotrexate therapy for 3 months.
Treatment: Adalimumab
Group IITreatment being tested
consists of 30 PsA patients who will receive Apremilast with methotrexate therapy for 3 months.
Treatment: Apremilast